XTL Biopharmaceuticals-ADRXTLB
13F holders, Q1 2026 (March 31)6holders
$2.41avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding XTL Biopharmaceuticals-ADR (XTLB) in their 13F filings. The largest holders were Noked Israel Ltd ($120K), SmartHarvest Portfolios, LLC ($32K) and Rhumbline Advisers ($14K).
- Company
- XTL Biopharmaceuticals-ADR
- CUSIP
- 98386D406
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $175K |
| Exits | 0 | $0 |
Ownership 6 holders
| Noked Israel Ltd | 0.02% | New | 49,722 | $120K |
| SmartHarvest Portfolios, LLC | 0.01% | New | 13,351 | $32K |
| Rhumbline Advisers | 0.00% | New | 5,987 | $14K |
| GAMMA Investing LLC | 0.00% | New | 3,388 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 244 | $588 |
| Morgan Stanley | 0.00% | New | 10 | $24 |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals-ADR the manager owns.